|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/01/15 Concordia International Corp. 40FR12B 36:10M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 40FR12B Registration of Securities of a Canadian Issuer -- HTML 40K
SEA'34 §12(b)
2: EX-99.1 Miscellaneous Exhibit HTML 404K
11: EX-99.10 Miscellaneous Exhibit HTML 21K
12: EX-99.11 Miscellaneous Exhibit HTML 110K
13: EX-99.12 Miscellaneous Exhibit HTML 373K
14: EX-99.13 Miscellaneous Exhibit HTML 43K
15: EX-99.14 Miscellaneous Exhibit HTML 266K
16: EX-99.15 Miscellaneous Exhibit HTML 137K
17: EX-99.16 Miscellaneous Exhibit HTML 105K
18: EX-99.17 Miscellaneous Exhibit HTML 52K
19: EX-99.18 Miscellaneous Exhibit HTML 380K
20: EX-99.19 Miscellaneous Exhibit HTML 217K
3: EX-99.2 Miscellaneous Exhibit HTML 225K
21: EX-99.20 Miscellaneous Exhibit HTML 30K
22: EX-99.21 Miscellaneous Exhibit HTML 19K
23: EX-99.22 Miscellaneous Exhibit HTML 80K
24: EX-99.23 Miscellaneous Exhibit HTML 31K
25: EX-99.24 Miscellaneous Exhibit HTML 86K
26: EX-99.25 Miscellaneous Exhibit HTML 848K
27: EX-99.26 Miscellaneous Exhibit HTML 457K
28: EX-99.27 Miscellaneous Exhibit HTML 215K
29: EX-99.28 Miscellaneous Exhibit HTML 243K
30: EX-99.29 Miscellaneous Exhibit HTML 27K
4: EX-99.3 Miscellaneous Exhibit HTML 470K
31: EX-99.30 Miscellaneous Exhibit HTML 24K
32: EX-99.31 Miscellaneous Exhibit HTML 25K
33: EX-99.32 Miscellaneous Exhibit HTML 24K
34: EX-99.33 Miscellaneous Exhibit HTML 17K
35: EX-99.34 Miscellaneous Exhibit HTML 15K
36: EX-99.35 Miscellaneous Exhibit HTML 13K
5: EX-99.4 Miscellaneous Exhibit HTML 533K
6: EX-99.5 Miscellaneous Exhibit HTML 251K
7: EX-99.6 Miscellaneous Exhibit HTML 376K
8: EX-99.7 Miscellaneous Exhibit HTML 25K
9: EX-99.8 Miscellaneous Exhibit HTML 20K
10: EX-99.9 Miscellaneous Exhibit HTML 20K
| EX-99.33 |
Exhibit 99.33
Concordia Healthcare Corp. Announces Change to Board of Directors
TORONTO, ONT. – December 22, 2014 - Concordia Healthcare Corp. (“Concordia” or the “Company”) (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that Paul Manning has resigned from the Board of Directors of the Company, effective January 2, 2015.
Mr. Manning will remain with the Company in an advisory role.
“We are grateful to Paul for his contributions and wish him success in his future endeavors,” said Ron Schmeichel, Non-Executive Chairman of the Board.
Mr. Manning served on Concordia’s Board of Directors since May 15, 2014, when the Company, through its subsidiary, acquired Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome (IBS) and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals. Mr. Manning was the founder of Revive Pharmaceuticals.
“Donnatal’s performance has exceeded our expectations and Paul played an important role in the integration of this asset into our diverse and growing portfolio of legacy pharmaceuticals,” said Mark Thompson, CEO of Concordia.
The Board of Directors will determine if it is preferable to fill the vacancy before the next annual meeting of shareholders and, if so, will follow established nominating procedures.
About Concordia
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. Concordia’s legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of the following products: ADHD-treatment Kapvay® (clonidine extended release tablets), head lice treatment Ulesfia® (benzyl alcohol) Lotion, asthma-related medication Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets), irritable bowel syndrome treatment Donnatal® (belladonna alkaloids, phenobarbital) and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. Concordia’s specialty healthcare distribution (SHD) division, Complete Medical Homecare, distributes medical supplies targeting diabetes and related conditions. Concordia’s orphan drugs division, Concordia Laboratories Inc., manufactures PHOTOFRIN®. PHOTOFRIN® is marketed by Pinnacle Biologics, Inc. in the United States.
Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; Lenexa, Kansas; Chicago, Illinois and Charlottesville, Virginia.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding Concordia and its business, which may include, but are not limited to, the performance of Concordia’s assets, the revenue-generating capabilities and/or potential of Concordia’s assets, Concordia’s financial strength, the continued and/or expected profitability of Concordia’s products and/or services, Concordia’s growth, the acquisition of additional products and/or assets (including orphan drugs and legacy products) and other factors. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Concordia’s management, and are based on assumptions and subject to risks and uncertainties. Although Concordia’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks relating to the use of Concordia’s products to treat certain diseases, the pharmaceutical industry, the failure to obtain regulatory approvals, risks associated with the acquisition of pharmaceutical products, economic factors, market conditions, acquisition opportunities, the inability to complete acquisitions, the equity markets generally, risks associated with growth and competition and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please visit www.concordiarx.com or contact:
Adam Peeler
TMX Equicom
416-815-0700 x 225
| This ‘40FR12B’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 6/1/15 | F-X | ||
| 1/2/15 | ||||
| 12/22/14 | ||||
| 5/15/14 | ||||
| List all Filings | ||||